Cremophor EL
Tóm tắt
Từ khóa
Tài liệu tham khảo
Jonkman-de Vries, 1994, Pharmaceutical development of (investigational) anticancer agents for parenteral use — a review, ECC Newsletter, 3, 11
Liu, 1997, Patient preferences for oral versus intravenous palliative chemotherapy, J. Clin. Oncol., 15, 110, 10.1200/JCO.1997.15.1.110
Hoffman, 1984, Polyoxythylenglycerol triricinoleat 35 DAC 1979, Pharm. Zeit., 129, 1730
Goldspiel, 1995, Guidelines for administration, 175
Adams, 1993, Taxol, J. Natl. Cancer Inst. Monogr., 15, 141
Rowinsky, 1993, Clinical toxicities encountered with paclitaxel (Taxol), Semin. Oncol., 20, 1
Weiss, 1990, Hypersensitivity reactions from Taxol, J. Clin. Oncol., 8, 1263, 10.1200/JCO.1990.8.7.1263
Eisenhauer, 1994, European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer, J. Clin. Oncol., 12, 2654, 10.1200/JCO.1994.12.12.2654
Szebeni, 1998, Complement activation by Cremophor EL as a possible contributer to hypersensitivity to paclitaxel, J. Natl. Cancer Inst., 90, 300, 10.1093/jnci/90.4.300
Watkins, 1997, Adverse reactions to intravenous anaesthetic induction agents, Br. Med. J., 2, 1084, 10.1136/bmj.2.6094.1084-a
Hüttel, 1980, Complement-mediated reactions to diazepam with Cremophor as solvent (stesolid MR), Br. J. Anaesth., 52, 77, 10.1093/bja/52.1.77
van Zuylen, 2000, Interrelationships of paclitaxel disposition, infusion duration and Cremophor EL kinetics in cancer patients, Anticancer Drugs, 11, 331, 10.1097/00001813-200006000-00003
Lorenz, 1977, Histamine release in dogs by Cremophor EL and its derivatives, Agent Actions, 7, 63, 10.1007/BF01964882
Rowinsky, 1991, Cardiac disturbances during the administration of Taxol, J. Clin. Oncol., 9, 1704, 10.1200/JCO.1991.9.9.1704
Theis, 1995, Anaphylactoid reactions in children receiving high-dose intravenous cyclosporine for reversal of tumor resistance, J. Clin. Oncol., 13, 2508, 10.1200/JCO.1995.13.10.2508
Volcheck, 1998, Anaphylaxis to intravenous cyclosporine and tolerance to oral cyclosporine, Am. Allergy Asthma Immunol., 80, 159, 10.1016/S1081-1206(10)62949-3
Bagnarello, 1977, Unusual lipoproteins induced by the vehicle of miconazole, N. Eng. J. Med., 296, 497, 10.1056/NEJM197703032960907
Kongshaug, 1991, Interaction of Cremophor EL with human serum, Int. J. Biochem., 23, 473, 10.1016/0020-711X(91)90176-N
Woodburn, 1994, The alteration of plasma lipoproteins by Cremophor EL, Photochem. Photobiol. B, 22, 197, 10.1016/1011-1344(93)06968-9
Sykes, 1994, Effects of Cremophor EL on distribution of taxol to serum lipoproteins, Br. J. Cancer, 70, 401, 10.1038/bjc.1994.317
Kessel, 1995, Fractionation of Cremophor EL delineates components responsible for plasma alterations and multidrug resistance reversal, Oncol. Res., 7, 207
Windebank, 1994, Potential neurotoxicity of the solvent vehicle for cyclosporine, J. Pharmacol. Exp. Ther., 268, 1051
Lesser, 1995, The distribution of systemically administered [3H]paclitaxel in rats, Cancer Chemother. Pharmacol., 37, 173
de Groen, 1987, Central nervous system toxicity after liver transplantation, N. Eng. J. Med., 317, 861, 10.1056/NEJM198710013171404
Sparreboom, 1997, Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine, Proc. Natl. Acad. Sci. USA, 94, 2031, 10.1073/pnas.94.5.2031
Verweij, 1994, Paclitaxel (Taxol) and docetaxel (Taxotere), Ann. Oncol., 5, 495, 10.1093/oxfordjournals.annonc.a058903
Podratz, 1993, Dialyzer associated neurotoxicity due to a change in fatty acid structure, Trans. Am. Soc. Neurochem., 24, 229
Brat, 1992, Emulsifier for intravenous cyclosporin inhibits neurite outgrowth, causes deficits in rapid axonal transport and leads to structural abnormalities in differentiating N1E.115 neuroblastoma, J. Pharmacol. Exp. Ther., 261, 803
Woodcock, 1990, Reversal of multidrug resistance phenotype with Cremophor EL, a common vehicle for water-insoluble vitamins and drugs, Cancer Res., 50, 4199
Friche, 1990, The solvents Cremophor EL and Tween 80 modulate daunorubicin resistance in the multidrug resistant Ehrlich ascites tumor, Cancer Commun., 2, 297
Schuurhuis, 1990, The polyethylene castor oil Cremophor EL modifies multidrug resistance, Br. J. Cancer, 62, 591, 10.1038/bjc.1990.335
Chervinsky, 1993, Cremophor EL enhances Taxol efficacy in a multi-drug resistant C13000 neuroblastoma cell line, Anticancer Res., 13, 93
Riehm, 1972, Potentiation of drug effect by Tween 80 in hamster cells resistant to actinomycin D and daunomycin, Cancer Res., 32, 1195
Coon, 1991, Solutol HS 15, nontoxic polyethylene esters of 12-hydroxystearic acid, reverses multidrug resistance, Cancer Res., 50, 4199
Zordan-Nudo, 1993, Effects of nonionic detergents on P-glycoprotein drug binding and reversal of multidrug resistance, Cancer Res., 53, 897
Woodcock, 1992, Reversal of multidrug resistance by surfactants, Br. J. Cancer, 66, 62, 10.1038/bjc.1992.217
Slater, 1995, Comparison of cyclosporin A, verapamil, PSC-833 and Cremophor EL as enhancing agents of VP-16 in murine lymphoid leukemias, Leuk. Res., 19, 543, 10.1016/0145-2126(95)00029-N
Watanabe, 1996, Cremophor EL reversed multidrug resistance in vitro but not in tumor-bearing mouse models, Anticancer Drugs, 7, 825, 10.1097/00001813-199611000-00002
Sparreboom, 1998, Disposition of Cremophor EL limits the potential of the multidrug resistance phenotype in vivo, Clin. Cancer Res., 4, 1937
Nooter, 1994, Clinical relevance of P-glycoprotein expression in hematological malignancies, Leuk. Res., 18, 233, 10.1016/0145-2126(94)90025-6
Fjällskog, 1993, Is Cremophor EL, the solvent for paclitaxel, cytotoxic?, Lancet, 342, 873, 10.1016/0140-6736(93)92735-C
Nygren, 1995, The cytotoxic activity of Taxol in primary cultures of tumour cells from patients is partly mediated by Cremophor EL, Br. J. Cancer, 71, 478, 10.1038/bjc.1995.97
Csóka, 1997, Differential activity of Cremophor EL and Paclitaxel in patients' tumour cells and human carcinoma cell lines in vitro, Cancer, 79, 1225, 10.1002/(SICI)1097-0142(19970315)79:6<1225::AID-CNCR23>3.0.CO;2-0
Bégin, 1988, Polyunsaturated fatty acid-induced cytotoxicity against tumour cells and its relationship to lipid peroxidation, J. Natl. Cancer Inst., 80, 188, 10.1093/jnci/80.3.188
Siegel, 1987, Cytotoxic effects of free fatty acids on ascites tumour cells, J. Natl. Cancer Inst., 78, 271
Burton, 1991, Oncolytic effects of fatty acids in mice and rats, Am. J. Clin. Nutr., 53, 1082, 10.1093/ajcn/53.4.1082S
Liebmann, 1994, The influence of Cremophor EL on the cell cycle effects of paclitaxel (Taxol) in human tumor cell lines, Cancer Chemother. Pharmacol., 33, 331, 10.1007/BF00685909
Webster, 1993, Measurement of CrEL following Taxol, J. Natl. Cancer Inst., 85, 1685, 10.1093/jnci/85.20.1685
Sparreboom, 1996, Determination of polyethylene-glyceroltriricinoleate 35 (Cremophor EL) in plasma by pre-column derivatization and reverse-phase high-performance liquid chromatography, J. Chromatogr. B, 681, 355, 10.1016/0378-4347(95)00544-7
Sparreboom, 1998, Quantification of Cremophor EL in human plasma samples using a calorimetric dye-binding microassay, Anal. Biochem., 255, 171, 10.1006/abio.1997.2467
Brouwer, 1998, Linearized colorimetric assay for Cremophor EL, Anal. Biochem., 261, 198, 10.1006/abio.1998.2746
Kunkel, 1999, Titrimetric determination of Cremophor EL in aqueous solutions and biofluids, J. Pharm. Biomed. Anal., 21, 911, 10.1016/S0731-7085(99)00212-5
Brouwer, 2000, Measurement of unbound paclitaxel in human plasma, Drug Metab. Dispos., 28, 1141
Rischin, 1996, Cremophor pharmacokinetics in patients receiving 3-, 6-, and 24-hour infusions of paclitaxel, J. Natl. Cancer Inst., 88, 1297, 10.1093/jnci/88.18.1297
Sparreboom, 1996, Nonlinear murine pharmacokinetics of paclitaxel results from the pharmaceutical vehicle Cremophor EL, Cancer Res., 56, 2112
van Tellingen, 1999, Rapid esterase-sensitive breakdown of polysorbate 80 and its impact on the plasma pharmacokinetics of docetaxel and metabolites in mice, Clin. Cancer Res., 5, 2918
Meerum-Terwogt, 2000, Cremophor EL pharmacokinetics in a phase I study of paclitaxel (Taxol) and carboplatin in non-small cell lung cancer patients, Anticancer Drugs, 11, 687, 10.1097/00001813-200010000-00003
Gelderblom, 1999, Disposition of [G-3H]paclitaxel in a patient with severely impaired renal function, Drug Metab. Dispos., 27, 1300
Gianni, 1997, Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer, J. Clin. Oncol., 15, 1906, 10.1200/JCO.1997.15.5.1906
Ellis, 1999, Inhibition of paclitaxel elimination in the isolated perfused rat liver by Cremophor EL, Cancer Chemother. Pharmacol., 43, 13, 10.1007/s002800050857
Sparreboom, 1999, Cremophor EL-mediated alteration of paclitaxel distribution in human blood, Cancer Res., 59, 1454
van Zuylen, 2001, Pharmacokinetic modeling of paclitaxel encapsulation in Cremophor EL micelles, Cancer Chemother. Pharmacol., 47, 309, 10.1007/s002800000215
Barre, 1988, Problems in therapeutic drug monitoring, Ther. Drug. Monit., 10, 133, 10.1097/00007691-198802000-00002
van der Burg MEL, de Wit R, Stoter G, Verweij J. Phase I study of weekly cisplatin and weekly or 4-weekly taxol: a highly active regimen in advanced epithelial cancer. Proc Am Soc Clin Oncol 1998, 17, 1370 (abstr).
Rowinsky, 1991, Sequences of taxol and cisplatin, J. Clin. Oncol., 9, 1692, 10.1200/JCO.1991.9.9.1692
Huizing, 1993, Pharmacokinetics of paclitaxel in a dose-escalating and dose-sequencing study in patients with non-small-cell lung cancer, J. Clin. Oncol., 15, 317, 10.1200/JCO.1997.15.1.317
de Vos, 1997, Differential modulation of cisplatin accumulation in leucocytes and tumor cell lines by the paclitaxel vehicle Cremophor EL, Ann. Oncol., 8, 1145, 10.1023/A:1008215720081
Ma, 1996, Docetaxel and paclitaxel inhibit DNA adduct formation and intracellular accumulation of cisplatin in human leukocytes, Cancer Chemother. Pharmacol., 36, 382, 10.1007/s002800050401
Badary, 2000, Differential alteration of cisplatin myelotoxicity by the paclitaxel vehicle Cremophor EL, Naunyn-Schmiedeberg Arch. Pharmacol., 261, 339, 10.1007/s002109900193
Bertoncello, 1995, Haematopoietic radioprotection by Cremophor EL, Int. J. Radiat. Biol., 67, 57, 10.1080/09553009514550071
Millward, 1998, Phase I trial of Cremophor EL with bolus doxorubicin, Clin. Cancer Res., 4, 2321
Holmes, 1996, Sequence-dependent alteration of doxorubicin pharmacokinetics by paclitaxel in a phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer, J. Clin. Oncol., 14, 2713, 10.1200/JCO.1996.14.10.2713